While the trials were successfully conducted and the vaccine regimens were safe and immunogenic, the resultant anti‐ENV binding (non‐neutralizing) antibodies and only moderate levels of CD4+ and class 1 restricted antigen‐specific CD8+ T cells, were insufficient to prevent HIV infection or rapidly kill HIV‐infected cells. This evidence concerns the gene CD8A and HIV infectious disease.